Checkpoint Therapeutics Inc (CKPT) Stock Price, Quote & News

Company Profile

Checkpoint Therapeutics, Inc., a commercial -stage immunotherapy and targeted oncology company, focuses on the acquisition, development, and commercialization of novel treatments for patients with solid tumor cancers in the United States and internationally. The company's lead antibody product candidate is UNLOXCYT, which is in Phase 1 clinical trial to treat patients with selected recurrent or metastatic cancers; and CK-302, a product candidate in preclinical trials for hematological malignanci...

Industry: Biotechnology

Sector: Healthcare

Phone: 781 652 4500

Fax: 646 619 4950

Website: checkpointtx.com

Address:

95 Sawyer Road, Suite 110, Waltham, United States

Bigtimemoney Jul. 17 at 12:58 PM

$CKPT when should we start hearing about any possible milestone achievements ? Anyone have any idea?

0 · Reply

Michl2000 Jul. 15 at 9:12 PM

$TPST $CKPT the BO price CKPK was the highest price the stock saw in the last 12 months. If this would be the case for TPST tomorrow, i'm quite happy and don't need much more. From my point of view it makes no sense only to have a look at the current share price.

0 · Reply

Scoooter Jul. 15 at 8:49 PM

$TPST $CKPT got a cancer drug approved and had to sell 2 months later for its current share price No premium This companies drug isn’t even approved It’s only phase 3 ready And it needs $100 million invested in the 3 trial on top of any acquisition Um… u guys thinking there will a premium are delusional

2 · Reply

FinSUN Jul. 8 at 7:17 AM

$FBIO $CKPT $DERM $MBIO I left emotions in investments long time ago... @makrodimutross has answered for me. You just need to check how deep and long insiders have been dealing with B. Riley, that - by the way - I already addressed in many posts. That is pure conflict of interest, as with 90% of the cases where insiders have dealt with B. Riley for both M/A and as ATM agents. Pretending the blame is just on the book runner, as makro calls them, is unrealistic.

0 · Reply

makrodimutross Jul. 8 at 6:18 AM

$FBIO $CKPT $DERM $MBIO Bear case is easy, but it's related to capital markets and not medical data or company assets. The company is solid, but they have left a trail of nasty with the institutional investors for the benefit of the book runners *someone call Marc Cohodes and ask him about B. Riley* One simple check on their balance sheet will reveal an approximate 3/4 billion in paid in capital... and only scraps to show for it (so far). Also note the CKPT sale was Not a success to anyone who participated in the March 2018 public offering of 4.6m shares at $4.35 per share. https://finance.yahoo.com/news/hedge-funds-never-bullish-fortress-122842690.html Opaleye was one of the names who previously held a significant position, but has since largely cashed out according to 13F filings. I am bullish on the company, and the high insider confidence, but watch out because this sector is ruthless to main street.

1 · Reply

KeepYourDayJob Jul. 7 at 8:42 PM

$FBIO $CKPT $DERM $MBIO Are you just emotional or have some facts?

0 · Reply

FinSUN Jul. 7 at 7:21 PM

$FBIO $CKPT $DERM $MBIO so it looks like insiders are involved as I suspected.

0 · Reply

FinSUN Jul. 7 at 3:26 PM

$FBIO $CKPT $DERM $MBIO meanwhile Mustang +500% 🤣 othwr catalysts... $CKPT sold, royalties in the pipe, $DERM Approvals and monetization...

0 · Reply

FinSUN Jul. 7 at 2:59 PM

$FBIO $CKPT $DERM $MBIO manipulation at its finest. The question is who will jump on it and break the short control. If insiders are mixed up with it, then unfortunately it will be nearly impossible.

0 · Reply

Chaser7252 Jul. 7 at 2:31 PM

Can someone give me the bear thesis on $FBIO? I've followed the company for quite some time and have now seen it's subsidiaries find success multiple times in $CKPT, $DERM, and now $MBIO. And yet, FBIO doesn't seem to move at all. What's the deal here? Am I missing something?

2 · Reply

Market Cap	370.71M
Revenue (ttm)	40,000.00
Net Income (ttm)	-56.24M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-140,600.01%
Debt to Equity Ratio	0.00

Volume	8,666,800
Avg Vol	1,808,080
Day's Range	N/A - N/A
Shares Out	87.02M
Stochastic %K	85%
Beta	1.18
Analysts	Sell
Price Target	$4.45